Shanghai Henlius Biotech Co. Ltd.

As its PD-L1-targeting antibody-drug conjugate (ADC) candidate HLX43 moves into a global-first Phase II trial in China and the US, Shanghai Henlius Biotech sees in the study a launchpad to lift the ag

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Rznomics To Partner With Lilly On

Roche says the potential for biosimilar competition to its Perjeta (pertuzumab) blockbuster HER2 inhibitor for breast cancer is “not a threat that we’re super worried about right now,” considering the

Sandoz has announced a deal worth up to $301m with Shanghai Henlius Biotech for rights to a Yervoy (ipilimumab) biosimilar in countries around the world. Targeting originator sales of $2.5bn achieved